Which VHL-associated tumours is Welireg (belzutifan) indicated to treat in adults when localised procedures are unsuitable or undesirable?

Welireg (belzutifan) is indicated for adults with VHL disease requiring treatment for associated renal cell carcinoma, central nervous system hemangioblastomas or pancreatic neuroendocrine tumours when localised procedures are unsuitable or undesirable.